What do systematic reviews say?

Very high protein vs low protein intake (restricted to studies meeting all a priori inclusion criteria)

The review found no eligible studies for this question.

• Higher versus lower protein intake in formula‐fed low birth weight infants 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Very high protein vs low protein intake (restricted to studies meeting all a priori inclusion criteria)

The review found no eligible studies for this question.

• Higher versus lower protein intake in formula‐fed low birth weight infants 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Very high protein vs low protein intake (restricted to studies meeting all a priori inclusion criteria)

The review found no eligible studies for this question.

• Higher versus lower protein intake in formula‐fed low birth weight infants 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

More intensive vs less intensive insulin therapy

It is very uncertain whether more intensive changes transplant or graft survival compared with less intensive insulin therapy (very low certainty).

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  RR 1.12 [0.32, 3.94]
  4 studies · 301 participants
  Very low

DPP‐4 inhibitors vs placebo

The review found no eligible studies for this question.

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DPP‐4 inhibitors vs placebo

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 32 participants
  Low

DPP‐4 inhibitors vs placebo

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 32 participants
  Low

DPP‐4 inhibitors vs placebo

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 32 participants
  Low

DPP‐4 inhibitors vs placebo

The review found no eligible studies for this question.

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DPP‐4 inhibitors vs placebo

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 51 participants
  Very low

DPP‐4 inhibitors vs placebo

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 51 participants
  Very low

DPP‐4 inhibitors vs insulin glargine

The review found no eligible studies for this question.

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DPP‐4 inhibitors vs insulin glargine

The review found no eligible studies for this question.

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DPP‐4 inhibitors vs insulin glargine

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 45 participants
  Very low

More intensive vs less intensive insulin therapy

It is very uncertain whether more intensive changes delayed graft function Time frame: 1 to 3 years compared with less intensive insulin therapy (very low certainty).

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  RR 0.63 [0.42, 0.93]
  2 studies · 153 participants
  Very low

DPP‐4 inhibitors vs insulin glargine

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 45 participants
  Very low

DPP‐4 inhibitors vs insulin glargine

The review found no eligible studies for this question.

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DPP‐4 inhibitors vs insulin glargine

The review found no eligible studies for this question.

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DPP‐4 inhibitors vs insulin glargine

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 45 participants
  Very low

DPP‐4 inhibitors vs insulin glargine

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 45 participants
  Very low